_11-new-drug-updates-in-solid-tumors-parp-inhibitors-in-ovarian-cancer-immunotherapeutics-and-other-agents.jpg "11) New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 37 min 60 sec
✓ Published: 09-Jan-2018
✓ Published: 09-Jan-2018
Description:
Edward Li, PharmD, MPH, BCOP, University of New England College of PharmacynnGet updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.nnThis activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology
Edward Li, PharmD, MPH, BCOP, University of New England College of PharmacynnGet updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.nnThis activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.webp "Prof Rana McKay (The University of California, San Diego, USA), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in PARP inhibitors in prostate cancer. nnThe panel analyses the secondary datasets from trials such as PROPEL 2, TALAPRO 2 and MAGNITUDE and discuss how it impacts our understanding of best practice with the use of PARP inhibitors in prostate cancer. nnThey cover the r")
_m2-evolving-landscape-of-parp-inhibitors-in-mcrpc-combination-with-anti-androgens.webp "In this video you'll learn about PARP inhibitors in prostate cancer, in particular the rationale behind combination treatment with anti-androgens from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno.nnWe are pleased to share that this video is part of a micro learning programme that is endorsed by ZERO Prostate Cancer and EAUN.You can find out more about ZERO at https://zerocancer.org/ and EAUN at https://nurses.uroweb.org/nnThe micro learning programme includes videos")
⏲ 2 min 41 sec ✓ 17-Jan-2023
_parp-inhibitors-for-castration-resistant-prostate-cancer.webp "Dr Grace A Martin speaks about the use of the PARP inhibitor olaparib for the treatment of metastatic castration-resistant prostate cancer.nnDr Martin provides a background on the use of PARP inhibitors in prostate cancer, explaining why there is a need to find a targeted treatment for these patients. She discusses some of the existing research in this area and reports on recent FDA approvals of PARP inhibitors for the treatment of prostate cancer. nnDr Martin describes her own clinical experien")
_parp-inhibitors-olaparib-and-talazoparib-as-treatment-for-metastatic-breast-cancer.webp "Dr Matteo Lambertini talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about two PARP inhibitor agents that are approved for treatment in metastatic breast cancer.nnHe explains that they have been studied in two similar randomised trials showing similarly promising results.nnDr Lambertini explains that going forward it is key to understand whether these agents can be used in the early setting but that trials are underway researching this.nnSign up to ecance")
⏲ 3 min 10 sec ✓ 18-Jun-2019
_mansoor-raza-mirza-md-on-reducing-toxicity-associated-with-parp-inhibitors-in-ovarian-cancer.webp "Mansoor Raza Mirza, MD, on Reducing Toxicity Associated With PARP Inhibitors in Ovarian Cancer from parp")
⏲ 1 min 12 sec ✓ 03-Jul-2019
_more-ovarian-cancer-patients-benefit-from-maintenance-combined-targeted-therapy.webp "Prof Isabella Ray-Coquard speaks to ecancer at ESMO 2019 in Barcelona about the PAOLA-1/ENGOT-ov25 Phase III trial, which showed the benefits of treating advanced ovarian cancer patients with bevacizumab and PARP inhibitor olaparib in the first-line setting. nnShe explains that this intensive regimen was given to patients both with and without a BRCA mutation. While both groups were found to have extended progression-free survival, this was more pronounced in the subgroup of patients with BRCA m")
⏲ 2 min 65 sec ✓ 28-Sep-2019
_latest-in-parp-inhibitors-and-combination-therapies-for-prostate-cancer.webp "Dr Dan George (Duke University School of Medicine, USA), Prof Noel Clarke (The Christie NHS Foundation Trust, Manchester, UK), Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) and Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA) discuss the latest in PARP inhibitors and combinations for prostate cancer. nnIn this discussion they cover the TALAPRO-2, PROpel and MAGNITUDE trials. They discuss the use of non-OS endpoints and combination therap")
⏲ 13 min 43 sec ✓ 19-Feb-2023
_parp-inhibitor-olaparib-as-treatment-for-pancreatic-cancer-patients-with-brca-gene-mutations.webp "Dr Hedy Kindler talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the POLO trial looking at the use of the PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutationsnnShe explains that this trial is the first phase III trial showing that a targeted treatment in a biomarker selective group of pancreatic cancer patients can improve progression free survival.nnDr Kindler reports that patients who received ol")
⏲ 1 min 78 sec ✓ 02-Jun-2019
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.jpg)
_m2-evolving-landscape-of-parp-inhibitors-in-mcrpc-combination-with-anti-androgens.jpg)
_parp-inhibitors-for-castration-resistant-prostate-cancer.jpg)
_parp-inhibitors-olaparib-and-talazoparib-as-treatment-for-metastatic-breast-cancer.jpg)
_mansoor-raza-mirza-md-on-reducing-toxicity-associated-with-parp-inhibitors-in-ovarian-cancer.jpg)
_more-ovarian-cancer-patients-benefit-from-maintenance-combined-targeted-therapy.jpg)
_latest-in-parp-inhibitors-and-combination-therapies-for-prostate-cancer.jpg)
_parp-inhibitor-olaparib-as-treatment-for-pancreatic-cancer-patients-with-brca-gene-mutations.jpg)
![[+]](/images/menu.gif){kind=small}